Third Wave's Q1 Revenues Slump 15 Percent as Surge in R&D Spending Widens Loss | GenomeWeb
NEW YORK (GenomeWeb News) — Third Wave Technologies today said first-quarter revenues slumped 15 percent as R&D spending surged 122 percent and net loss widened 34 percent.  
 
Total receipts for the three months ended March 31 decreased to $6.7 million from $7.9 million year over year.
 
Revenue from clinical molecular diagnostics products rose 27 percent to $6 million from $4.7 million, but receipts from research products declined 81 percent to $569,000 from $3 million.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.